# Nature Communications

Source: https://onco.cc/journals/nature-communications/  
OnCo record `nature-communications` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Springer Nature's large fully open-access multidisciplinary journal, carrying a high volume of cancer genomics, immunology, AI and translational papers.

## Summary

Nature Communications (Nat Commun) is Springer Nature's large, fully open-access multidisciplinary journal, founded in 2010, publishing under CC BY licences with peer-review files often published alongside the article. It publishes thousands of articles a year across science, and in cancer it is a major venue for genomic and single-cell studies, immunology, AI and computational methods, and secondary analyses of trial biospecimens. Its readers are researchers across disciplines who want open-access primary research. Within OnCo it is linked from the biographies of Woong-Yang Park, Robert Gatenby, Giovanni Blandino and Viktor Adalsteinsson, and a reader would use it for the high volume of cancer genomics and translational papers it carries.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: Nat Commun
- Publisher: Springer Nature
- Scope: general science
- Access: open-access

## Sources

- Nature Portfolio: https://www.nature.com

## Connected records

- key papers: [Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance](https://onco.cc/key-papers/paper-yamazaki-nat-commun/), [Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis](https://onco.cc/key-papers/paper-nct05077449-nat-commun-2025/), [Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients](https://onco.cc/key-papers/paper-sausen-ctdna-pancreatic-resection-nat-commun-2015/), [Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen](https://onco.cc/key-papers/paper-menden-nat-commun/), [Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer](https://onco.cc/key-papers/paper-pritchard-complex-msh2-msh6-hypermutated-prostate-nat-commun-2014/), [Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations](https://onco.cc/key-papers/paper-santosh-kesari-nat-commun-2026/), [Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial](https://onco.cc/key-papers/paper-nct05724563-nat-commun-2025/), [Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial](https://onco.cc/key-papers/paper-de-groot-nat-commun/), [Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer](https://onco.cc/key-papers/paper-lin-gallbladder-neoplasia-carcinoma-evolution-nat-commun-2021/), [Genomic characterization of malignant progression in neoplastic pancreatic cysts](https://onco.cc/key-papers/paper-noe-cyst-malignant-progression-genomics-nat-commun-2020/), [Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories](https://onco.cc/key-papers/paper-taylor-germline-brca2-evolutionary-trajectories-nat-commun-2017/), [Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate](https://onco.cc/key-papers/paper-pandey-gallbladder-elf3-nat-commun-2020/), [Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer](https://onco.cc/key-papers/paper-zhang-nat-commun/), [Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes](https://onco.cc/key-papers/paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021/), [Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study](https://onco.cc/key-papers/paper-nct04956640-nat-commun-2026/), [Sarcoma classification by DNA methylation profiling](https://onco.cc/key-papers/paper-koelsche-nat-commun/), [Segment anything in medical images](https://onco.cc/key-papers/paper-ma-nat-commun/), [The molecular origin and taxonomy of mucinous ovarian carcinoma](https://onco.cc/key-papers/paper-cheasley-mucinous-ovarian-genomics-nat-commun-2019/), [Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 +, RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis](https://onco.cc/key-papers/paper-mountaineer-nat-commun-2026-update/), [Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets](https://onco.cc/key-papers/paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015/)
- people: [Giovanni Blandino](https://onco.cc/people/giovanni-blandino/), [Jihui Hao](https://onco.cc/people/jihui-hao/), [Magdolna Dank](https://onco.cc/people/magdolna-dank/), [Rachel Ramoni](https://onco.cc/people/rachel-ramoni/), [Robert A. Gatenby](https://onco.cc/people/robert-gatenby/), [Viktor A. Adalsteinsson](https://onco.cc/people/viktor-adalsteinsson/), [Woong-Yang Park](https://onco.cc/people/park-woong-yang/), [Wouter de Laat](https://onco.cc/people/wouter-de-laat/)

---
JSON: https://onco.cc/api/v1/entities/nature-communications.json